<!DOCTYPE html>
<html>
 <head>
  <meta charset="utf-8"/>
  <meta content="width=device-width" initial-scale="1" name="viewport"/>
  <style>
   /* Create a running element */
      #header-and-footer {
        position: running(header-and-footer);
        text-align: right;
      }

      /* Add that running element to the top and bottom of every page */
      @page {
        @top {
          content: element(header-and-footer);
        }
        @bottom {
          content: element(header-and-footer);
        }
      }

      /* Add a page number */
      #page-number {
        content: "Page " counter(page);
      }

      @page { size: A4 }

      /* Create a title page with a full-bleed background and no header */
      /* Create a soa page with landscape orientation */
      #title-page {
        page: title-page;
      }
      .soa-page {
        page: soa-page
      }

      @page title-page {
        @top {
          content: "";
        }
      }

      @page soa-page {
        size: A4 landscape
      }

      #title-page h1 {
        padding: 200px 0 40px 0;
        font-size: 30px;
      }

      /* Dynamically create a table of contents with leaders */
      #table-of-contents a {
        content: target-content(attr(href)) leader('.') target-counter(attr(href), page);
        color: #000000;
        text-decoration: none;
        display: block;
        padding-top: 5px;
      }

      /* Float the footnote to a footnotes area on the page */
      .footnote {
        float: footnote;
        font-size: small;
      }

      .page {
        page-break-after: always;
      }

      body {
        counter-reset: chapter;
        font-family: 'Times New Roman';
        color: #000000;
      }

      .usdm-warning {
        font-style: italic;
        color: red;
      }

      .soa-body-text {
        font-size: 10px;
        text-align: center
      }

      .soa-activity-text {
        font-size: 10px;
        text-align: left
      }

      .soa-footnote-text {
        font-size: 12px;
        text-align: left
      }

      .usdm-highlight {
        background-color: LightGray !important;
      }

      .usdm-highlight p {
        background-color: LightGray;
      }

      p .usdm-highlight {
        background-color: LightGray;
      }

      .usdm-highlight-link {
        text-decoration:none;
      }
  </style>
  <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;800&amp;display=swap" rel="stylesheet"/>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap-icons@1.9.1/font/bootstrap-icons.css" rel="stylesheet" type="text/css"/>
  <link crossorigin="anonymous" href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css" integrity="sha384-T3c6CoIi6uLrA9TneNEoa7RxnatzjcDSCmG1MXxSR1GAsXEV/Dwwykc2MPK8M2HN" rel="stylesheet"/>
  <script crossorigin="anonymous" integrity="sha384-C6RzsynM9kWDrMNeT87bh95OGNyZPhcTNXj1NW7RuBCsyN/o0jlpcV8Qyq46cDfL" src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/js/bootstrap.bundle.min.js">
  </script>
 </head>
 <body>
  <div class="page" id="title-page">
   <div class="container">
    <div class="row">
     <div class="col-md-8 offset-md-2 text-center">
      <h1>
       Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease
      </h1>
     </div>
    </div>
    <div class="row mt-5">
     <div class="col-md-8 offset-md-2 text-center">
      <p class="usdm-warning">
       Note:
      </p>
      <p class="usdm-warning">
       This document is generated from content held within the Unified Studies Definitions Model. It is for test purposes only.
      </p>
     </div>
    </div>
   </div>
   <div id="header-and-footer">
    <span id="page-number">
    </span>
   </div>
  </div>
  <div class="page">
   <div xmlns="http://www.w3.org/1999/xhtml">
    <table>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Sponsor Confidentiality Statement:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Full Title:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Trial Acronym:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        H2Q-MC-LZZT
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Protocol Identifier:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        H2Q-MC-LZZT
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Original Protocol:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Version Number:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        2
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Version Date:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        2006-06-01
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Amendment Identifier:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        1
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Amendment Scope:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        Global
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Compound Codes(s):
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Compound Name(s):
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Trial Phase:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        Phase II Trial
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Short Title:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        Xanomeline (LY246708)
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Sponsor Name and Address:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        Eli Lilly, Lilly Corporate Ctr, Indianapolis, , IN, 4628, United States of America
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Regulatory Agency Identifier Number(s):
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        NCT12345678
       </p>
      </td>
     </tr>
     <tr>
      <th style="vertical-align: top; text-align: left">
       <p>
        Sponsor Approval Date:
       </p>
      </th>
      <td style="vertical-align: top; text-align: left">
       <p>
        2006-07-01
       </p>
      </td>
     </tr>
    </table>
   </div>
  </div>
  <div class="page">
   <div class="page" id="toc-page">
    <div id="table-of-contents">
     <a href="#section-1">
     </a>
     <a href="#section-2">
     </a>
     <a href="#section-3">
     </a>
     <a href="#section-4">
     </a>
     <a href="#section-5">
     </a>
     <a href="#section-6">
     </a>
     <a href="#section-7">
     </a>
     <a href="#section-8">
     </a>
     <a href="#section-9">
     </a>
     <a href="#section-10">
     </a>
     <a href="#section-11">
     </a>
     <a href="#section-12">
     </a>
     <a href="#section-13">
     </a>
     <a href="#section-14">
     </a>
     <a href="#section-15">
     </a>
    </div>
    <div align="center">
     <br/>
     <p class="usdm-warning">
      Note:
     </p>
     <p class="usdm-warning">
      The table of contents is auto generated upon PDF production and only includes first level sections.
     </p>
    </div>
    <div id="header-and-footer">
     <span id="page-number">
     </span>
    </div>
   </div>
  </div>
  <div class="page">
   <h1 id="section-1">
    1 PROTOCOL SUMMARY
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-1.1">
    1.1 Protocol Synopsis
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-1.2">
    1.2 Trial Schema
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-1.3">
    1.3 Schedule of Activities
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-2">
    2 INTRODUCTION
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-2.1">
    2.1 Purpose of Trial
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-2.2">
    2.2 Summary of Benefits and Risks
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-3">
    3 TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-3.1">
    3.1 Primary Objectives
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
    <table>
     <tr>
      <td style="vertical-align: top; text-align: left">
       <p>
        To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).
       </p>
      </td>
      <td style="vertical-align: top; text-align: left">
       <p>
        Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Week 24
       </p>
       <p>
        Video-referenced Clinician’s Interview-based Impression of Change (CIBIC+) at Week 24
       </p>
      </td>
     </tr>
     <tr>
      <td style="vertical-align: top; text-align: left">
       <p>
        To document the safety profile of the xanomeline TTS.
       </p>
      </td>
      <td style="vertical-align: top; text-align: left">
       <p>
        Adverse events
       </p>
       <p>
        Vital signs (weight, standing and supine blood pressure, heart rate)
       </p>
       <p>
        Laboratory evaluations (Change from Baseline)
       </p>
      </td>
     </tr>
     <tr>
      <td style="vertical-align: top; text-align: left">
       <p>
        To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.
       </p>
      </td>
      <td style="vertical-align: top; text-align: left">
       <p>
        Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Weeks 8 and 16
       </p>
       <p>
        Video-referenced Clinician’s Interview-based Impression of Change (CIBIC+) at Weeks 8 and 16
       </p>
       <p>
        Mean Revised Neuropsychiatric Inventory (NPI-X) from Week 4 to Week 24
       </p>
      </td>
     </tr>
    </table>
   </div>
  </div>
  <div class="page">
   <h1 id="section-4">
    4 TRIAL DESIGN
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-4.1">
    4.1 Description of Trial Design
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-4.1.1">
    4.1.1 Participant Input into Design
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-4.2">
    4.2 Rationale for Trial Design
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
    <p>
     Previous studies of the oral formulation have shown that xanomeline tartrate may improve behavior and cognition. Effects on behavior are manifest within 2 to 4 weeks of initiation of treatment. The same studies have shown that 8 to 12 weeks are required to demonstrate effects on cognition and clinical global assessment. This study is intended to determine the acute and chronic effects of the TTS formulation in AD; for that reason, the study is of 26 weeks duration. Dosage specification has been made on the basis of tolerance to the xanomeline TTS in a clinical pharmacology study (H2Q-EW-LKAA), and target plasma levels as determined in studies of the oral formulation of xanomeline (H2Q-MC-LZZA).
    </p>
   </div>
  </div>
  <div class="">
   <h3 id="section-4.2.1">
    4.2.1 Rationale for Comparator
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
    <p>
     The parallel dosing regimen maximizes the ability to make direct comparisons between the treatment groups. The use of placebo allows for a blinded, thus minimally biased, study. The placebo treatment group is a comparator group for efficacy and safety assessment.
    </p>
    <p>
     Two interim analyses are planned for this study. The first interim analysis will occur when 50% of the patients have completed Visit 8 (8 weeks). If required, the second interim analysis will occur when 50% of the patients have completed Visit 12 (24 weeks).
    </p>
   </div>
  </div>
  <div class="">
   <h3 id="section-4.2.2">
    4.2.2 Rationale for Adaptive or Novel Trial Design
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-4.2.3">
    4.2.3 Other Trial Design Considerations
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-4.3">
    4.3 Access to Trial Intervention After End of Trial
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-4.4">
    4.4 Start of Trial and End of Trial
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-5">
    5 TRIAL POPULATION
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-5.1">
    5.1 Selection of Trial Population
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
    <p>
     For Lilly studies, the following definitions are used:
    </p>
    <div>
     <div>
      <strong>
       Screen
      </strong>
     </div>
     <div>
      <p>
       Screening is the act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study.
      </p>
      <p>
       In this study,
       <strong>
        screening
       </strong>
       will include asking the candidate preliminary questions (such as age and general health status) and conducting invasive or diagnostic procedures and/or tests (for example, diagnostic psychological tests, x-rays, blood draws). Patients will sign the consent at their screening visit, thereby consenting to undergo the screening procedures and to participate in the study if they qualify.
      </p>
     </div>
    </div>
    <div>
     <div>
      To
      <strong>
       enter
      </strong>
     </div>
     <div>
      <p>
       Patients
       <strong>
        entered
       </strong>
       into the study are those from whom informed consent for the study has been obtained. Adverse events will be reported for each patient who has
       <strong>
        entered
       </strong>
       the study, even if the patient is never assigned to a treatment group (
       <strong>
        enrolled
       </strong>
       ).
      </p>
     </div>
    </div>
   </div>
   <div>
    <div>
     To
     <strong>
      enroll
     </strong>
    </div>
    <div>
     <p>
      Patients who are enrolled in the study are those who have been assigned to a treatment group. Patients who are entered into the study but fail to meet criteria specified in the protocol for treatment assignment will not be enrolled in the study.
     </p>
    </div>
   </div>
   <p>
    At Visit 1, patients who meet the enrollment criteria of Mini-Mental State Examination (MMSE) score of 10 to 23 (Attachment LZZT.6), Hachinski Ischemia Score ≤4 (Attachment LZZT.8), a physical exam, safety labs, ECG, and urinalysis, will proceed to Visit 2 and Visit 3. At Visit 3, patients whose CNS imaging and other pending labs from Visit 1 satisfy the inclusion criteria (Section 3.4.2.1) will be enrolled in the study. Approximately 300 patients with a diagnosis of probable mild to moderate AD will be enrolled in the study.
   </p>
  </div>
  <div class="">
   <h2 id="section-5.2">
    5.2 Rationale for Trial Population
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-5.3">
    5.3 Inclusion Criteria
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
    <p>
     Patients may be included in the study only if they meet
     <strong>
      all
     </strong>
     the following criteria:
    </p>
    <table>
     <tr>
      <td style="vertical-align: top; text-align: left">
       <p>
        1
       </p>
      </td>
      <td style="vertical-align: top; text-align: left">
       <p>
        Subjects shall be between 50.0 and 100.0
       </p>
      </td>
     </tr>
     <tr>
      <td style="vertical-align: top; text-align: left">
       <p>
        2
       </p>
      </td>
      <td style="vertical-align: top; text-align: left">
       <p>
        Patients with Probable Mild to Moderate Alzheimer's Disease as defined by the NINCDS and the ADRDA guidelines (Attachment LZZT.7)
       </p>
      </td>
     </tr>
     <tr>
      <td style="vertical-align: top; text-align: left">
       <p>
        3
       </p>
      </td>
      <td style="vertical-align: top; text-align: left">
       <p>
        MMSE score of 10 to 23
       </p>
      </td>
     </tr>
    </table>
   </div>
  </div>
  <div class="">
   <h2 id="section-5.4">
    5.4 Exclusion Criteria
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
    <p>
     Patients may be excluded in the study for
     <strong>
      any
     </strong>
     of the following reasons:
    </p>
    <table>
     <tr>
      <td style="vertical-align: top; text-align: left">
       <p>
        9
       </p>
      </td>
      <td style="vertical-align: top; text-align: left">
       <p>
        Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline.
       </p>
      </td>
     </tr>
    </table>
   </div>
  </div>
  <div class="">
   <h2 id="section-5.5">
    5.5 Lifestyle Considerations
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-5.5.1">
    5.5.1 Meals and Dietary Restrictions
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-5.5.2">
    5.5.2 Caffeine, Alcohol, Tobacco, and Other Habits
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
    <p>
     Not applicable
    </p>
   </div>
  </div>
  <div class="">
   <h3 id="section-5.5.3">
    5.5.3 Physical Activity
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-5.5.4">
    5.5.4 Other Activity
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-5.6">
    5.6 Screen Failures
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-6">
    6 TRIAL INTERVENTION AND CONCOMITANT THERAPY
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-6.1">
    6.1 Description of Trial Intervention
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-6.2">
    6.2 Rationale for Trial Intervention
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-6.3">
    6.3 Dosing and Administration
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.3.1">
    6.3.1 Trial Intervention Dose Modification
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-6.4">
    6.4 Treatment of Overdose
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-6.5">
    6.5 Preparation, Handling, Storage and Accountability
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.5.1">
    6.5.1 Preparation of Trial Intervention
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.5.2">
    6.5.2 Handling and Storage of Trial Intervention
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.5.3">
    6.5.3 Accountability of Trial Intervention
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-6.6">
    6.6 Participant Assignment, Randomisation and Blinding
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.6.1">
    6.6.1 Participant Assignment
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.6.2">
    6.6.2 Randomisation
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.6.3">
    6.6.3 Blinding and Unblinding
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
    <p>
     The study will be double-blind. To further preserve the blinding of the study, only a minimum number of Lilly and CRO personnel will see the randomization table and codes before the study is complete.
    </p>
    <p>
     Emergency codes generated by a computer drug-labeling system will be available to the investigator. These codes, which reveal the patients treatment group, may be opened during the study only if the choice of follow-up treatment depends on the patient’s therapy assignment.
    </p>
    <p>
     The investigator should make every effort to contact the clinical research physician prior to unblinding a patient’s therapy assignment. If a patient’s therapy assignment is unblinded, Lilly must be notified immediately by telephone. After the study, the investigator must return all sealed and any opened codes.
    </p>
   </div>
  </div>
  <div class="">
   <h2 id="section-6.7">
    6.7 Trial Intervention Compliance
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-6.8">
    6.8 Concomitant Therapy
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.8.1">
    6.8.1 Prohibited Concomitant Therapy
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.8.2">
    6.8.2 Permitted Concomitant Therapy
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.8.3">
    6.8.3 Rescue Therapy
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-6.8.4">
    6.8.4 Other Therapy
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-7">
    7 DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-7.1">
    7.1 Discontinuation of Trial Intervention
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-7.1.1">
    7.1.1 Criteria for Permanent Discontinuation of Trial Intervention
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-7.1.2">
    7.1.2 Temporary Discontinuation or Interruption of Trial Intervention
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-7.1.3">
    7.1.3 Rechallenge
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-7.2">
    7.2 Participant Withdrawal from the Trial
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-7.3">
    7.3 Lost to Follow-Up
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-7.4">
    7.4 Trial Stopping Rules
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-8">
    8 TRIAL ASSESSMENTS AND PROCEDURES
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.1">
    8.1 Screening/Baseline Assessments and Procedures
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.2">
    8.2 Efficacy Assessments and Procedures
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.3">
    8.3 Safety Assessments and Procedures
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.3.1">
    8.3.1 Physical Examination
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.3.2">
    8.3.2 Vital Signs
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.3.3">
    8.3.3 Electrocardiograms
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.3.4">
    8.3.4 Clinical Laboratory Assessments
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.3.5">
    8.3.5 Suicidal Ideation and Behaviour Risk Monitoring
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.4">
    8.4 Adverse Events and Serious Adverse Events
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.1">
    8.4.1 Definitions of AE and SAE
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.2">
    8.4.2 Time Period and Frequency for Collecting AE and SAE Information
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.3">
    8.4.3 Identifying AEs and SAEs
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.4">
    8.4.4 Recording of AEs and SAEs
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.5">
    8.4.5 Follow-up of AEs and SAEs
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.6">
    8.4.6 Reporting of SAEs
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.7">
    8.4.7 Regulatory Reporting Requirements for SAEs
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.8">
    8.4.8 Serious and Unexpected Adverse Reaction Reporting
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.9">
    8.4.9 Adverse Events of Special Interest
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.4.10">
    8.4.10 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.5">
    8.5 Pregnancy and Postpartum Information
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.5.1">
    8.5.1 Participants Who Become Pregnant During the Trial
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.5.2">
    8.5.2 Participants Whose Partners Become Pregnant
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.6">
    8.6 Medical Device Product Complaints for Drug/Device Combination Products
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.6.1">
    8.6.1 Definition of Medical Device Product Complaints
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.6.2">
    8.6.2 Recording of Medical Device Product Complaints
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.6.3">
    8.6.3 Time Period and Frequency for Collecting Medical Device Product Complaints .
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.6.4">
    8.6.4 Follow-Up of Medical Device Product Complaints
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.6.5">
    8.6.5 Regulatory Reporting Requirements for Medical Device Product Complaints
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.7">
    8.7 Pharmacokinetics
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.8">
    8.8 Genetics
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.9">
    8.9 Biomarkers
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-8.1">
    8.1 Immunogenicity Assessments
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-8.1.1">
    8.1.1 Medical Resource Utilisation and Health Economics
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-9">
    9 STATISTICAL CONSIDERATIONS
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.1">
    9.1 Analysis Sets
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.2">
    9.2 Analyses Supporting Primary Objective(s)
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-9.2.1">
    9.2.1 Statistical Model, Hypothesis, and Method of Analysis
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-9.2.2">
    9.2.2 Handling of Intercurrent Events of Primary Estimand(s)
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-9.2.3">
    9.2.3 Handling of Missing Data
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-9.2.4">
    9.2.4 Sensitivity Analysis
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-9.2.5">
    9.2.5 Supplementary Analysis
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.3">
    9.3 Analysis Supporting Secondary Objective(s)
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.4">
    9.4 Analysis of Exploratory Objective(s)
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.5">
    9.5 Safety Analyses
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.6">
    9.6 Other Analyses
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.7">
    9.7 Interim Analyses
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.8">
    9.8 Sample Size Determination
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-9.9">
    9.9 Protocol Deviations
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-10">
    10 GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-10.1">
    10.1 Regulatory and Ethical Considerations
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-10.2">
    10.2 Committees
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-10.3">
    10.3 Informed Consent Process
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-10.4">
    10.4 Data Protection
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-10.5">
    10.5 Early Site Closure or Trial Termination
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-11">
    11 GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-11.1">
    11.1 Quality Tolerance Limits
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-11.2">
    11.2 Data Quality Assurance
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-11.3">
    11.3 Source Data
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-12">
    12 APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-12.1">
    12.1 Further Details and Clarifications on the AE Definition
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-12.2">
    12.2 Further Details and Clarifications on the SAE Definition
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-12.3">
    12.3 Severity
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-12.4">
    12.4 Causality
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-13">
    13 APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-13.1">
    13.1 Contraception and Pregnancy Testing
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-13.1.1">
    13.1.1 Definitions Related to Childbearing Potential
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-13.1.2">
    13.1.2 Contraception
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h3 id="section-13.1.3">
    13.1.3 Pregnancy Testing
   </h3>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-13.2">
    13.2 Clinical Laboratory Tests
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-13.3">
    13.3 Country/Region-Specific Differences
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="">
   <h2 id="section-13.4">
    13.4 Prior Protocol Amendments
   </h2>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-14">
    14 APPENDIX: GLOSSARY OF TERMS
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
  <div class="page">
   <h1 id="section-15">
    15 APPENDIX: REFERENCES
   </h1>
   <div xmlns="http://www.w3.org/1999/xhtml">
   </div>
  </div>
 </body>
</html>
